Terms: = Ovarian cancer AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF AND Treatment
441 results:
1. PARP Inhibitors in Breast cancer: a Short Communication.
Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
[TBL] [Abstract] [Full Text] [Related]
2. Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer.
Chen L; Fan T; Wang M; Zhu CY; Feng WY; Li Y; Yang H
Expert Opin Ther Targets; 2024; 28(1-2):83-95. PubMed ID: 38235574
[TBL] [Abstract] [Full Text] [Related]
3. Danggui Shaoyao San protects cyclophosphamide-induced premature ovarian failure by inhibiting apoptosis and oxidative stress through the regulation of the SIRT1/p53 signaling pathway.
Chen H; Zhang G; Peng Y; Wu Y; Han X; Xie L; Xu H; Chen G; Liu B; Xu T; Pang M; Hu C; Fan H; Bi Y; Hua Y; Zhou Y; Luo S
J Ethnopharmacol; 2024 Apr; 323():117718. PubMed ID: 38181933
[TBL] [Abstract] [Full Text] [Related]
4. The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era.
García-Illescas D; Mazzeo R; García-Durán C; Oaknin A
Curr Opin Obstet Gynecol; 2024 Apr; 36(2):104-111. PubMed ID: 38170620
[TBL] [Abstract] [Full Text] [Related]
5. A review of racial disparities in ovarian cancer and clinical trials.
Ali M; Tewari KS
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):23-27. PubMed ID: 38170549
[TBL] [Abstract] [Full Text] [Related]
6. Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives.
Salutari V; Giudice E; Lorusso D
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):9-17. PubMed ID: 38170548
[TBL] [Abstract] [Full Text] [Related]
7. Contemporary Trends in Laparoscopy and ovarian Sparing Surgery for ovarian Torsion in the Pediatric Population.
Huerta CT; Rodriguez C; Parreco J; Thorson CM; Sola JE; Perez EA
J Pediatr Surg; 2024 Mar; 59(3):393-399. PubMed ID: 37968152
[TBL] [Abstract] [Full Text] [Related]
8. Two-pronged microenvironmental modulation of metal-oxidase cascade catalysis and metabolic intervention for synergistic tumor immunotherapy.
Song Q; Gao H; Sun S; Li Y; Wu X; Yang J; Wang B; Zhang Y; Wang L
Acta Biomater; 2024 Jan; 173():378-388. PubMed ID: 37925121
[TBL] [Abstract] [Full Text] [Related]
9. Guizhi Fuling Formulation: A review on chemical constituents, quality control, pharmacokinetic studies, pharmacological properties, adverse reactions and clinical applications.
Liu X; Chen L; Sun P; Zhan Z; Wang J
J Ethnopharmacol; 2024 Jan; 319(Pt 2):117277. PubMed ID: 37802375
[TBL] [Abstract] [Full Text] [Related]
10. A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
Cameron JM; Sala A; Antoniou G; Brennan PM; Butler HJ; Conn JJA; Connal S; Curran T; Hegarty MG; McHardy RG; Orringer D; Palmer DS; Smith BR; Baker MJ
Br J Cancer; 2023 Nov; 129(10):1658-1666. PubMed ID: 37717120
[TBL] [Abstract] [Full Text] [Related]
11. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial.
Bülow NS; Warzecha AK; Nielsen MV; Andersen CY; Holt MD; Petersen MR; Sopa N; Zedeler A; Englund AL; Pinborg A; Grøndahl ML; Skouby SO; Macklon NS
Hum Reprod; 2023 Nov; 38(11):2154-2165. PubMed ID: 37699851
[TBL] [Abstract] [Full Text] [Related]
12. Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction.
Smits MAJ; Schomakers BV; van Weeghel M; Wever EJM; Wüst RCI; Dijk F; Janssens GE; Goddijn M; Mastenbroek S; Houtkooper RH; Hamer G
Hum Reprod; 2023 Nov; 38(11):2208-2220. PubMed ID: 37671592
[TBL] [Abstract] [Full Text] [Related]
13. Family size for women with primary ovarian insufficiency and their relatives.
Verrilli LE; Allen-Brady K; Johnstone EB; Alvord MA; Welt CK
Hum Reprod; 2023 Oct; 38(10):1991-1997. PubMed ID: 37632248
[TBL] [Abstract] [Full Text] [Related]
14. Evidence-based guideline: unexplained infertility†.
; Romualdi D; Ata B; Bhattacharya S; Bosch E; Costello M; Gersak K; Homburg R; Mincheva M; Norman RJ; Piltonen T; Dos Santos-Ribeiro S; Scicluna D; Somers S; Sunkara SK; Verhoeve HR; Le Clef N
Hum Reprod; 2023 Oct; 38(10):1881-1890. PubMed ID: 37599566
[TBL] [Abstract] [Full Text] [Related]
15. Network pharmacology and experimental validation on yangjing zhongyu decoction against diminished ovarian reserve.
Liu J; Wei B; Ma Q; Shi D; Pan X; Liu Z; Li J; Zhao P
J Ethnopharmacol; 2024 Jan; 318(Pt B):117023. PubMed ID: 37567422
[TBL] [Abstract] [Full Text] [Related]
16. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract] [Full Text] [Related]
17. O-RADS MRI SCORE: An Essential First-Step Tool for the Characterization of Adnexal Masses.
Thomassin-Naggara I; Dabi Y; Florin M; Saltel-Fulero A; Manganaro L; Bazot M; Razakamanantsoa L
J Magn Reson Imaging; 2024 Mar; 59(3):720-736. PubMed ID: 37550825
[TBL] [Abstract] [Full Text] [Related]
18. ovarian preservation in gynecologic oncology: current indications and techniques.
Bizzarri N; Pavone M; Loverro M; Querleu D; Fagotti A; Scambia G
Curr Opin Oncol; 2023 Sep; 35(5):401-411. PubMed ID: 37498120
[TBL] [Abstract] [Full Text] [Related]
19. Current limits of conservative treatment in ovarian cancer.
Gracia M; Alonso-Espías M; Zapardiel I
Curr Opin Oncol; 2023 Sep; 35(5):389-393. PubMed ID: 37498109
[TBL] [Abstract] [Full Text] [Related]
20. Association of infertility with type and timing of menopause: a prospective cohort study.
Scime NV; Brown HK; Shea AK; Brennand EA
Hum Reprod; 2023 Sep; 38(9):1843-1852. PubMed ID: 37451681
[TBL] [Abstract] [Full Text] [Related]
[Next]
